Jesús F. San-Miguel, Heinz Ludwig
Moderator: Heinz Ludwig
09:05 - 09:25Genomics in myeloma: pathogenic and clinical implications
Martin Kaiser
09:25 - 09:50How important are epigenetics in MM
Felipe Prósper
09:50 - 10:10Druggable myeloma therapeutics. Pathogenetic pathways
Enrique Ocio
10:10 - 10:25Experts' discussion around 5 burning questions:
1. What techniques?: clinical meaning of mutations
2. The number of genetics lesions and percentage of abnormal cells matter for clinical decisions?
3. What is the meaning of genetic changes in MGUS and SMM?
4. Clinical future for epigenetics
5. What are the most relevant pathways and drugs in myeloma?
Discussants: Martin Kaiser, Felipe Prósper, Enrique Ocio, Pieter Sonneveld
Moderator: Jesús F. San-Miguel
10:40 - 11:001. Difficult to treat MM (extramedullary, CNS, oligosecretory, solitary, PCL, biochemical relapse).
Kwee Yong
11:00 - 11:202. MGUS with systemic manifestations.
Joan Bladé
11:20 - 11:35Discussion
Moderator: Heinz Ludwig
11:50 - 12:05NGS
Nikhil C. Munshi
12:05 - 12:20Immunophenotyping
Bruno Paiva
12:20 - 12:35MRI and CT-PET
Philippe Moreau
12:35 - 12:55Experts' discussion around 5 burning topics:
1. New response criteria
2. Optimal MRD technique
3. Prognostic factors or biomarker for treatment
4. Should we stratify patients?
5. Should we implement PET in routine clinical practice?
Discussants: Nikhil C. Munshi, Bruno Paiva, Philippe Moreau, Jesús F. San-Miguel
Moderator: Philippe Moreau
13:45 - 14:05Smoldering myeloma
M. Victoria Mateos
14:05 - 14:20Experts' discussion on 4 burning topics:
1. How to deffine high risk
2. Delay progression or cure?
3. Risk adapted management
4. Will the concept of smoldering disappear?
Discussants: M. Victoria Mateos, Michele Cavo, Kwee Yong, Nikhil C. Munshi
Moderator: Jesús F. San-Miguel
14:35 - 14:55Induction and transplant
Philippe Moreau
14:55 - 15:15Consolidation and maintenance
Michele Cavo
15:15 - 15:30Experts' discussion on 5 burning topics:
1. Best induction
2. Early vs. late transplant
3. One vs. two
4. Consolidation & maintenance
5. High risk
Discussants: Philippe Moreau, Michele Cavo, Joan Bladé, Meletios A. Dimopoulos
Moderator: Heinz Ludwig
15:45 - 16:05Bases for immunotherapy in MM and novel antibodies
Niels van de Donk
16:05 - 16:25Clinical results with CAR-T cells and other adoptive therapies
Paula Rodríguez-Otero
16:25 - 16:40Experts' discussion on 4 burning topics:
1. Is CAR-T the future?
2. CAR-T plus anti-myeloma drugs
3. Bispecific antibodies or CAR-T
4. Industry or academia
Discussants: Niels van de Donk, Paula Rodríguez-Otero, Philippe Moreau, Pieter Sonneveld
Moderator: Jesús F. San-Miguel
16:55 - 17:153. Genomics and microenvironment: what a myeloma doctor should know.
Nikhil C. Munshi
17:15 - 17:454. Emergencies and supportive care (cord compression, RI, hyperCa, bone disease, infections…).
Heinz Ludwig
17:45 - 18:00Discussion